INTRODUCTION

Review question / Objective: To investigate whether zinc supplementation is associated with lower mortality in patients with chronic heart failure.

Condition being studied: Randomised controlled trials comparing zinc supplementation with a placebo or no treatment for mortality were included. Independent data extraction was conducted and study quality assessed. A meta analysis was carried out by using fixed effects and random effects models to calculate risk ratio of death in the group receiving zinc supplementation and the control group.

METHODS

Search strategy: One of the authors conducted the search of several databases: Medline (Ovid), Embase (Ovid), the Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform to identify ongoing or unpublished eligible trials.
the Cochrane Central Register of Controlled Trials (CENTRAL), from inception to 31 December 2021. We also searched ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform to identify ongoing or unpublished eligible trials. To maximise the search for relevant articles, we reviewed reference lists of identified trials and systematic reviews. We did not apply language restrictions.

**Participant or population:** Patients with chronic heart failure.

**Intervention:** Znic supplementation

**Comparator:** Chronic heart failure patients with a placebo or no treatment

**Study designs to be included:** Randomised controlled trials comparing Znic supplementation with a placebo or no treatment.

**Eligibility criteria:** Randomised controlled trials comparing vitamin D supplementation with a placebo or no treatment for mortality were included. Independent data extraction was conducted and study quality assessed.

**Information sources:** Databases: Medline (Ovid), Embase (Ovid), the Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform to identify ongoing or unpublished eligible trials.

**Main outcome(s):** All cause mortality.

**Quality assessment / Risk of bias analysis:** Two researchers independently assessed the quality of all included trials by using the Cochrane Collaboration risk of bias tool. They also examined the quality of evidence for outcomes using the grading of recommendations assessment, development, and evaluation (GRADE) approach.

**Strategy of data synthesis:** We performed statistical analyses using RevMan (version 5.3.3; The Cochrane Collaboration) and the meta package in R (version 3.4.3; R Project for Statistical Computing). Analyses for all outcomes were conducted on an intention to treat basis. We used risk ratios and their associated 95% confidence intervals to assess outcomes, and considered a P value less than 0.05 to be statistically significant. We assessed heterogeneity using the I2 test. If significant heterogeneity was not present (I2<50%), we used fixed effects models to pool outcomes; we used random effects models when significant heterogeneity was present (I2≥50%). The possibility of small study effects was assessed qualitatively by visual estimate of the funnel plot and quantitatively by calculation of the Egger test, the Begg test, and the Harbord test.

**Subgroup analysis:** We performed several subgroup analyses to test interactions according to dose; type of zinc; timing of treatment (daily and intermittently); and mean age (≥70 and <70 years). We conducted retrospective subgroup analyses based on length of follow-up (at least three years and less than three years); year of publication (before 2015 and in or after 2015); sex (female and both sexes); residential status (community and institution); bolus (yes and no).

**Sensitivity analysis:** We conducted sensitivity analyses by excluding trials with high or unknown risk of bias; excluding trials with high risk or unknown risk of bias of the different domains; excluding quasi randomised or cluster randomised trials; excluding the largest trial; excluding trials with a follow-up of less than one year; using random effect models.

**Country(ies) involved:** China.

**Keywords:** Zn, Znic, Znic supplementation, Chronic heart failure, Systematic review, Meta analysis

**Contributions of each author:**
Author 1 - Bin Zhang - Conceived the study and designed the protocol and selected the studies and extracted the relevant information.

Email: 452551332@qq.com
Author 2 - Ming Zhang - Conceived the study and designed the protocol and selected the studies and extracted the relevant information.
Email: zhangming8298@126.com
Author 3 - Cao-Jie Lu - Performed the literature search and synthesised the data and wrote the first draft of the paper.
Email: 450122361@qq.com
Author 4 - Li-Zhi Liu - Selected the studies and extracted the relevant information and synthesised the data and wrote the first draft of the paper.
Email: 273782406@qq.com
Author 5 - Chen Jiang - Selected the studies and extracted the relevant information and synthesised the data and wrote the first draft of the paper.
Email: jiangchen666@163.com
Author 6 - Ming-Jin Zhu - conceived the study and designed the protocol.
Email: zhumingjin@zcmu.edu.cn